IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Mycobacterium Vaccae for Injection (Trade Name "Vaccae") is a kind of bio-products developed by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.,and got "The New Drug Certificate "in 1999. Vaccae has been approved for adjuvant therapy of tuberculosis(TB), and is also the only recommended drug in TB immunotherapy by WHO. It was approved for production and sale by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd. in 2001, and got favourable comment in therapy of tuberculosis.
The purpose of this study is to add new indications for Vaccae, mainly to prevent Tuberculosis for high risk groups of Tuberculosis Infection . In December 2012, China Food and Drug Administration approved of the plan "Phase III Clinical Study of Efficacy and Safety of Mycobacterium Vaccae to Prevent Tuberculosis in high risk groups of Tuberculosis Infection". In the test, 10,000 cases whose skin tests of PPD are strongly positive are enrolled. Using random, double-blind, and placebo-controlled methods, the study is carried out to evaluate the efficacy and safety of Vaccae in preventing Tuberculosis. Meanwhile, in this test, TB incidence and degree of pathological changes of experimental group are lower than that of control group, and no drug-related SAEs are reported in treatment groups.
| Condition | Intervention | Phase |
|---|---|---|
| Tuberculosis | Drug: Vaccae Drug: placebo | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Prevention |
| Official Title: | Phase III Clinical Study of Efficacy and Safety of Mycobacterium Vaccae to Prevent Tuberculosis in High Risk Groups of Tuberculosis Infection |
- The whole TB incidence after injection of Vaccae [ Time Frame: Terminal Stage: two years after the last group of subjects enrolled ]Medium-term: one year after the last group of subjects enrolled or after observation of 38 cases of the disease, Terminal Stage: two years after the last group of subjects enrolled or after observation of 76 cases of the disease
- Lesion degree (Bacteriology indicators, cavity) of patients [ Time Frame: two years after the last group of subjects enrolled or after observation of 76 cases of the disease ]Medium-term: one year after the last group of subjects enrolled or after observation of 38 cases of the disease, Terminal Stage: two years after the last group of subjects enrolled or after observation of 76 cases of the disease
- Systemic and local reactions and adverse events [ Time Frame: within 30 days after last dosing ]within 30 days after last dosing
- The relation between skin test results and paroxysm of TB-PPD [ Time Frame: Terminal Stage: two years after the last group of subjects enrolled or after observation of 76 cases of the disease ]Medium-term: one year after the last group of subjects enrolled or after observation of 38 cases of the disease, Terminal Stage: two years after the last group of subjects enrolled or after observation of 76 cases of the disease
| Estimated Enrollment: | 10000 |
| Study Start Date: | October 2013 |
| Estimated Study Completion Date: | June 2017 |
| Estimated Primary Completion Date: | April 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Vaccae
Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
|
Drug: Vaccae
One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
Other Name: Mycobacterium vaccae for Injection
|
|
Placebo Comparator: Placebo
Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally
|
Drug: placebo
One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
Other Name: Vaccae Lyophilized stabilizers
|
Detailed Description:
The Main Purpose of the Study:
- Evaluation of efficacy of Vaccae to prevent Tuberculosis in high risk groups of Tuberculosis Infection.
The Secondary Purpose of the Study:
- Evaluation of Lesion Degree ( Bacteriology Indicators, Cavity) of patients and its relationship with Skin Test results of TB-PPD after Injection of Vaccae into the high risk groups.
- Evaluation of Changes in Humoral Immunity and Cellular Immunologic Response Before and After Injection of Vaccae
Test Hypothesis:
In the test, TB incidence and degree of pathological changes of experimental group are lower than that of control group, and no drug-related SAEs are reported in treatment groups
Blinding and Random:
Using random, double-blind, and placebo-controlled methods, evaluation of the efficacy and safety of Vaccae.
Using block randomization method, a random sequence was generated by the statistics personnel in Fourth Military Medical University Clinical Evaluation Center using SAS9.1.3 statistical software
The Unblinding includes the first time of Unblinding and the second time of Unblinding. The first time of Unblinding only distinguish groups , and the second time of Unblinding will uncover the final Blind Codes.
The Blind Codes of the design produce at one time, and unblinding will be carried out respectively at the first year and the second year after the beginning of the experiment.
Eligibility| Ages Eligible for Study: | 15 Years to 65 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged from 15 to 65 years old, all genders.
- Skin test of Tuberculin Pure Protein Derivative (TB-PPD) is strongly positive ( the average diameter of PPD skin test induration is greater than or equal to 15mm,and（or）local blisters, necrosis).
- Agreed to participate in the test and sign the informed consent.
- Subjects agreed to participate in the experiments and voluntarily signed the informed consent. (guardians of 15-17- year-old subjects should agree, meanwhile).
- The subjects should comply with the requirements of the clinical trial protocol and be Followed.
- Have not participated in any other clinical trial for nearly three months.
- Women of childbearing age from 15 to 49 years should agree with urine pregnancy tests and take effective birth control measures in two years after the medication.
- Axillary temperature is normal.
Exclusion Criteria:
The first injection drug exclusion criteria :
- Suffering from any other serious disease, e.g. during cancer treatment, autoimmune disease, progressive atherosclerosis, diabetes accompanied with complications, chronic obstructive pulmonary disease (COPD) needing oxygen therapy, acute or progressive liver or kidney disease, congestive heart failure, etc.
- Known allergy to experiment drugs
- People with history of specific diagnosis of TB, extrapulmonary tuberculosis or have been cured
- People have history of allergy, convulsions, epilepsy, cerebropathy, neurological symptoms and signs
- Patients who have impaired or abnormal immune function, e.g. patients treated with immunosuppressor or immunopotentiator, received immunoglobulin preparation or blood products or plasma extraction outside the gastrointestinal tract in 3 months, human immunodeficiency virus or related diseases
- Oral corticosteroids
- Patients who have been using oral corticosteroids for more than 1 week, or hormone medication in vitro for a long time
- Acute febrile illness and infection
- Pregnant or lactating women, or women who have birth plan in following 2 years
- Any other cases that may influence the test evaluation
The second-sixth injection drug exclusion criteria :
- Subjects whose compliance is poor, and can not take medicine on time or according to the amount
- Patients who are using medicine and food that can influence the result
- Pregnant subjects during the test
- Patients who are reluctant to continue and require exit
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01979900
| China, Guangxi | |
| Jin Chengjiang Center for Diseases Control and Prevention, Hechi, Guangxi | |
| Hechi, Guangxi, China, 547000 | |
| Liucheng County Diseases Control and Prevention, Liuzhou, Guangxi | |
| Liuzhou, Guangxi, China, 545000 | |
| Liuzhou Center for Diseases Control and Prevention, Liuzhou, Guangxi | |
| Liuzhou, Guangxi, China, 545000 | |
| Rongshui County Diseases Control and Prevention, Liuzhou, Guangxi | |
| Liuzhou, Guangxi, China, 545000 | |
| Principal Investigator: | Guoai Si, Director | Jin Chengjiang Center for Diseases Control and Prevention, Hechi, Guangxi |
| Principal Investigator: | Mingqiang Li, Director | Jin Chengjiang Center for Diseases Control and Prevention, Liuzhou, Guangxi |
| Principal Investigator: | Keshua Meng, Director | Rongshui County Diseases Control and Prevention, Liuzhou, Guangxi |
| Principal Investigator: | Debiao Qiao, Director | Liucheng County Diseases Control and Prevention, Liuzhou, Guangxi |
More Information
Additional Information:
Publications:
| Responsible Party: | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| ClinicalTrials.gov Identifier: | NCT01979900 History of Changes |
| Other Study ID Numbers: |
LTao |
| Study First Received: | November 4, 2013 |
| Last Updated: | December 27, 2016 |
Keywords provided by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.:
|
TB Infection Lesion Degree Bacteriology Indicators |
Cavity Humoral Immunity Cellular Immunologic Response |
Additional relevant MeSH terms:
|
Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections |
ClinicalTrials.gov processed this record on July 07, 2017